EKOS catheters are already FDA cleared for peripheral use, where the company is engaged in a series of limited clinical trials in order to further validate the value of its technology. Simultaneously, clinical trials are also underway to further prove the utility in stroke patients. "I am very gratified to have completed this financing round on a timely basis, aided by the efforts of NGN Capital, MedVentures, Morgan Stanley, and EGS Capital. The financing proceeds will be used to provide growth capital for EKOS to expand its marketing and production infrastructure. During the next 18 months, the company expects to double its staff, from 50 to 100 employees," explained Peter Rule, Chairman of EKOS.
Kenneth S. Abramowitz, Managing General Partner, represented NGN Houston Colt 45s Hat
EKOS holds 25 key patents covering the pioneering use of low energy ultrasound catheters to dissolve blood clots in the brain and legs. This advanced minimally invasive technology significantly improves the speed and efficacy of traditional micro catheters, thereby allowing neurosurgeons, interventional neuroradiologists, interventional radiologists, and vascular surgeons to more quickly and confidently dissolve blood clots. Early clinical data shows that EKOS catheters are capable of opening arteries more often than Chicago Cubs Hat Bear traditional techniques that are only 50% efficacious.
Peter Rule, formerly President, CEO, and Chairman New Era Caps 2014 Swag
of Percusurge, Inc., serves as Chairman and interim CEO of EKOS. Doug Hansmann, co founder, is the General Manager. The strong pipeline of products will be advanced by a seasoned management team of leading experts in the field of micro catheters.
Capital as the lead partner in this investment and will hold a board seat. "I am very excited to join the Board of EKOS and look forward to helping guide the company's successful entry into the marketplace."
NEW YORK, Feb. 18 /PRNewswire/ Funds advised by NGN Capital participated in the financing of a syndicate, along with MedVentures, Morgan Stanley, and EGS Capital in an $18 million Series B financing of EKOS Corporation, located in Bothell, Washington. EKOS is focused on developing and commercializing novel high technology ultrasound enhanced micro catheters for dissolving blood clots in the brain or in the peripheral arteries in the legs.
EKOS is a privately held high technology medical device company focused on developing and marketing ultrasound enhanced micro catheters to dissolve blood clots in the brain and legs in conjunction with thrombolytic agents. The company is headquartered in Bothell, Washington and at present has 50 employees.
1 Raises 18 Million In Series B New Era Kansas City Royals
Chicago Cubs Cap
New Era Snapbacks Uk
Ny Hats Nz
New Era New York Giants
Hermes Belt For Sale Uk
Gucci Belt Green Red Black
New Era Womens Caps
Detroit Tigers Hat Orange
Detroit Tigers Hat New Era
Hermes Belt Ebay
Michael Kors Belt Brown
Houston Astros Cap
Chicago Cubs Hat Vintage
Hermes Belt Mens Black